VJHemOnc is committed to improving our service to you

EHA 2019 | Hu5F9 plus rituximab to overcome resistance in refractory lymphoma

VJHemOnc is committed to improving our service to you

Mark Roschewski

Lymphoma cells often use CD47 as a “don’t eat me” signal; if this antigen is blocked, the signal is removed and the lymphoma cell can be targeted by the immune system for autophagy. Here, Mark Roschewski of the National Cancer Institute, Bethesda, MD, discusses how the anti-CD47 antibody Hu5F9 can be used in combination with rituximab to overcome drug resistance in refractory lymphomas. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter